Saudi Chemical Company Holding (SCCH) has struck a deal with GlaxoSmithKline to make pharmaceutical products in the Kingdom.
SCCH unit AJA Pharmaceutical Industries will team up with GlaxoSmithKline Consumer Healthcare Saudi in a five-year production deal worth SR100 million (US$27 million), the company said in a Saudi stock exchange filing on Thursday, June 3.
The new partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector, said SCCH CEO Thamer Al-Muhid. “Our mission is to be the partner of choice,” he said.
Saudi Arabia aims to diversify its economy away from oil by adding more high value jobs at home and replacing imports with domestic manufacturing in key sectors such as pharmaceuticals.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI